Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Aroa Biosurgery Ltd
ARXAroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand. Address: 64 Richard Pearse Drive, Auckland, New Zealand, 2022
Analytics
WallStreetin tavoitehinta
1.43 AUDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut ARX
Osinkoanalytiikka ARX
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria ARX
Osakkeen arvostus ARX
Talousasiat ARX
Tuloksia | 2019 | Dynamiikka |